Skip to content
Review Open access

Left atrial appendage occlusion: an alternative to anticoagulation in atrial fibrillation

Oct 2026 · Frontiers in Cardiovascular Medicine · Vol 13 · 0 citations · 75 references
Medicine

TL;DR

Data indicate that LAAO reduces non-procedure-related bleeding but does not decrease all-cause major bleeding, intracranial haemorrhage, or mortality, and may carry a higher risk of ischaemic stroke than DOAC.

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia. Global Burden of Disease estimates indicate that 52.6 million individuals were living with AF or atrial flutter in 2021, and one in three to one in five persons are expected to develop AF during their lifetime. AF is associated with an increased risk of stroke, systemic thromboembolism, and death. Oral anticoagulation (OAC) is the first-line strategy for preventing AF-associated embolism. However, embolic events still occur in 1%–4% of anticoagulated patients per year, major bleeding occurs in 2%–4% per year, and long-term adherence to direct oral anticoagulants (DOAC) is incomplete. Left atrial appendage occlusion (LAAO) was developed as a mechanical alternative to address these unmet needs. The evidence base has changed substantially over the last 2 years: three randomized controlled trials comparing LAAO with DOAC—OPTION, CHAMPION-AF, and CLOSURE-AF—have now reported. In this update, we summarize the pathophysiological rationale, the technical aspects of the procedure, and the totality of the randomized and observational evidence, including a 2026 meta-analysis of 5,890 randomized patients. Taken together, these data indicate that LAAO reduces non-procedure-related bleeding but does not decrease all-cause major bleeding, intracranial haemorrhage, or mortality, and may carry a higher risk of ischaemic stroke than DOAC. LAAO remains an established option for patients with contraindications to or intolerance of long-term OAC. In DOAC-eligible patients, it has become a randomized-tested alternative, but current evidence supports an individualized, shared decision rather than a universal offer. We outline the remaining controversies—patient selection, device-related thrombus, peri-device leak, post-procedural antithrombotic therapy, and the interpretation of observational data—and the trials designed to resolve them.

Read PDF

Similar papers

Review Open access Sep 2026

Who can benefit from percutaneous left atrial appendage closure? Recent advances.

Atrial fibrillation (AF) confers a substantial risk of stroke. Direct  oral anticoagulants (DOACs) are highly effective for stroke prevention and form the cornerstone of AF management. Nevertheless, many eligible patients do not receive or do not maintain long-term anticoagulation because of bleeding risk, prior hemorr...

P. Osmančík, M. Hozman · 0 citations
Review Open access Nov 2026

Left atrial appendage occlusion in atrial fibrillation: contemporary techniques, clinical outcomes, and future directions

Left atrial appendage occlusion (LAAO) is an important strategy for stroke prevention in patients with non-valvular atrial fibrillation (AF) who have contraindications to long-term oral anticoagulation. We differentiate this review from existing literature by integrating recent controversial trial data and device-speci...

Ahmad Siddiqi, S. I. Aaqil, Sara Sohail et al. · 0 citations
Review Open access Oct 2026

Left Atrial Appendage Occlusion vs Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis.

BACKGROUND Left atrial appendage occlusion (LAAO) has emerged as a non-pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION-AF and CLOSURE-AF trials, an updated synthesis of evidence is warranted to clarif...

Ahmed Nazmy, A. Abouelmagd, Ahmed Sobhy et al. · 0 citations
Open access Oct 2026

Left atrial appendage occlusion for atrial fibrillation–related stroke despite chronic oral anticoagulation

Data on the benefit of percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) who experience stroke despite chronic oral anticoagulation (OAC) are limited and not always consistent. To evaluate the association between LAAO and recurrent stroke or mortality using a pre...

L. Giovachini, J. Mesnier, T. Pommier et al. · 0 citations
Open access Oct 2026

Left Atrial Appendage Closure Versus Oral Anticoagulation for Prevention of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: An Updated Meta-Analysis of 7004 Patients Across Six Randomized Trials.

INTRODUCTION Left atrial appendage closure (LAAC) is an emerging alternative for stroke prevention in patients with atrial fibrillation (AF) who are unsuitable for long-term oral anticoagulants (OACs). However, its efficacy and safety relative to OACs remain uncertain. METHODS Three databases were searched up to Apri...

Aymen Ahmed, N. Paryani, Muteia Shakoor et al. · 0 citations
Review Open access Sep 2026

Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation

Background Left atrial appendage occlusion (LAAO) is a treatment option to prevent thromboembolic events in patients with atrial fibrillation. However, it remains unclear whether LAAO offers superior efficacy and safety compared with oral anticoagulation for these patients. Objectives This study aimed to assess the eff...

Yuriko Hiruma, Tadao Aikawa, I. Kawamura et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.